Page 49 - 《中国药科大学学报》2025年第5期
P. 49

第  56 卷第  5 期  齐 磊,等:二甲双胍通过促进醛酮还原酶             AKR1C3 降解抑制肝细胞癌恶性进展的机制研究                    581
                  A           HepG2                  HepG2               HCC-LM3               HCC-LM3

                      HA-Ub K48R  +  +       HA-Ub K63R  +  +     HA-Ub K48R  +  +     HA-Ub K63R  +  +
                       Metformin  −  +        Metformin  −  +     Metformin  −  +       Metformin  −  +
                      Chloroquine  +  +      Chloroquine  +  +    Chloroquine  +  +    Chloroquine  +  +


                       IP:AKR1C3  HA         IP:AKR1C3  HA        IP:AKR1C3  HA         IP:AKR1C3  HA



                        AKR1C3                 AKR1C3               AKR1C3               AKR1C3
                        AKR1C3                 AKR1C3               AKR1C3               AKR1C3
                       Input  β-actin         Input  β-actin       Input  β-actin       Input  β-actin


                  B                                  IP:AKR1C3  C                    D
                            Input  lgG  IP:p62  Input  lgG            shNC  shp62-1 shp62-2  HCC-LM3
                     AKR1C3            AKR1C3                                           1.5   n.s.
                                                                 p62
                        p62               p62                                           1.0
                             HepG2              HepG2         AKR1C3                    Relative AKR1C3 expression
                     AKR1C3            AKR1C3                                           0.5
                                                               β-actin
                        p62               p62                        HCC-LM3             0
                            HCC-LM3            HCC-LM3                                     shNC shp62-1 shp62-2
                  E                         250       n.s. n.s.  F
                     Metformin −  +  −  −  +  +    ***                 Input  IP:p62        Input  IP:p62
                     shp62-1 −  −  +  −  +  −
                     shp62-2 −  −  −  +  −  +     ***           Metformin  −  +  −  +  Metformin  −  +  −  +
                                            150
                    AKR1C3                Relative AKR1C3 level  /(% of control) 200  **  p62  p62
                       p62                  100                AKR1C3               AKR1C3
                     β-actin                 50                 β-actin              β-actin
                                              0
                              HCC-LM3    Metformin −  +  −  −  +  +      HCC-LM3              HepG2
                                          shp62-1  −  −  +  −  +  −
                                          shp62-2  −  −  −  +  −  +
                  G      DAPI        p62       AKR1C3      Merge     H                     150
                                                                      Metformin  −  +  −  +          ***
                                                                     Compound C −  −  +  +  100  ***
                    PBS                                               AKR1C3             Relative AKR1C3 level  /(% of control)
                                                                      P-AMPK               50
                                                                       AMPK
                                                                       β-actin              0
                                                                                           Con     Compound C
                                                                                           Metformin  Combination
                    HBSS                                             I         Chloroquine  +  +  +
                                                                                Metformin
                                                                               Compound C − −  + −  + +
                                                                                    LC3-I
                                                                                IP:AKR1C3  AKR1C3
                                                                                   LC3-II
                    Metformin                                                     AKR1C3
                                                                                    LC3-I
                                                                                   LC3-II
                                                                                 Input
                                                                                   β-actin
               Figure 5    MET promotes p62-mediated AKR1C3 selective autophagic degradation ( x ± s)
               A: After exogenous transfer of K48 or K63 mutant ubiquitin, effect of MET on the ubiquitination of AKR1C3 was observed by Co-IP assay;
               B: Interaction of AKR1C3 with p62 was determined by Co-IP assay; C: Protein amount of AKR1C3 in HCC-LM3 cells after knockdown of
               p62 was observed by Western blot assay; D: mRNA level of AKR1C3 in HCC-LM3 cells after knockdown of p62 was observed by RT-
               PCR; E: Effect of MET on AKR1C3 protein content after knockdown of p62 was detected in HCC-LM3 cells by Western blot assay; F:
               Effect of MET on interaction of AKR1C3 with p62 was determined by Co-IP assay in HCC-LM3 cells; G: Effect of MET on colocalization of
               AKR1C3 with p62 was determined by confocal microscopy in HCC-LM3 cells;H: Effect of MET on AKR1C3 protein content was detected
               after the treatment of Compound C by Western blot assays in HCC-LM3 cells; I: Effect of MET on interaction of AKR1C3 with LC3 was
               determined after the treatment of Compound C by Co-IP assay in HCC-LM3 cells
               *P < 0.05, **P < 0.01, ***P < 0.001; n.s.:P > 0.05
   44   45   46   47   48   49   50   51   52   53   54